AI-Powered Insights into the Treatment of Hemophilia A

1. AI-Powered Insights into the Treatment of Hemophilia A Hemophilia A, a genetic disorder characterized by a deficiency in clotting Factor VIII, places a significant burden on patients and healthcare providers. Managing this condition remains challenging due to the unpredictability of bleeds, the prohibitive costs of treatment, and a lack of fully effective long-term therapies. As a result, innovative treatments and patient support programs are critical to improving the quality of life and outcomes for people with Hemophilia A without inhibitors. GrapheneAI’s study provided the client withAI-powered insightsto strategize their marketing for their drug targeting this disorder. AI-Powered Insights: Hemophilia A Treatment Landscape 1.Treatment Options and Challenges Current treatments for Hemophilia A primarily involve Factor VIII replacement therapy. However, this option does not eliminate the risk of bleeding episodes, leading patients and healthcare providers to explore additional solutions. While effective, Factor VIII treatments are expensive, and patients often face high out-of- pocket costs due to limited insurance coverage. Patients and their families express a desire for affordable treatments and more comprehensive insurance support. 2.The Growing Role of X The drug X has emerged as a promising prophylactic option, providing patients with a more convenient and effective alternative to traditional IV-administered Factor VIII. X’s ease of administration and positive clinical trial results have made it a popular choice among healthcare providers (HCPs), especially for patients struggling with adherence to IV treatments or those developing inhibitors. In fact, within a duration of

2. one year, there was a 20–25% increase in the intent to prescribe X, reflecting growing confidence in its benefits. Across various countries, HCPs have noted X’s potential to revolutionize Hemophilia A care by offering effective prophylaxis and reducing the need for Factor VIII infusions. However, there remain concerns over X’s cost-effectiveness and potential side effects, which have prompted some HCPs to request more real-world data to assess its efficacy and safety further. AI-Powered Insights into the Perspectives on Factor VIII Treatments 1.Standard Half-Life (SHL) vs. Extended Half-Life (EHL) Factor VIII TheAI-powered insightsfrom the study stated that despite X’s increasing popularity, traditional Factor VIII products remain integral to treatment regimens. SHL Factor VIII treatments are widely used, though some patients and providers are interested in EHL versions, which may offer better protection for more active individuals. However, the hesitancy to switch to EHL products is notable among HCPs. Many providers are reluctant due to the lack of insurance coverage, and EHL treatments are not yet part of standard care guidelines in many countries. 2.A and B: Key Players in Factor VIII Therapy A and B, two widely used Factor VIII products, are perceived differently by HCPs. A enjoys a formidable reputation as a reliable, long-standing therapy. In some countries, there are patient “loyalists” who prefer A over newer options. B, an EHL version of A, is not widely viewed as a breakthrough treatment due to its higher cost without a significant value increase. HCPs are unlikely to prescribe B unless it becomes standard care, as its benefits are primarily relevant to a specific subset of patients. For our client, which manufactures both A and B, promoting these products effectively in a competitive market will involve emphasizing A’s established efficacy and supporting B’s adoption through better economic data and clinical guidelines. AI-Powered Insights: Patient and Caregiver Perspectives 1.Satisfaction with Factor VIII Treatment Feedback from adult patients and caregivers reflects varying levels of satisfaction with Factor VIII therapy. Adults tend to feel marginally more satisfied than caregivers of young children, who often wish for more flexible and less burdensome treatment options. Hemophilia advocacy groups play an essential role in providing support and education to patients and families, creating a sense of community, and advocating for improved access to care. 2.Role of Patient Advocacy Groups (PAGs) Patient Advocacy Groups (PAGs) have become increasingly important for patients and families affected by Hemophilia A. Beyond offering emotional support, PAGs in countries like China, Russia, South Korea, and Türkiye work directly with drug companies, assist patients with insurance documentation, and lobby for policy changes. These groups are critical for raising awareness and pushing for better resources for managing Hemophilia A. 3.Patient Support Programs (PSPs) Patient Support Programs (PSPs) are essential in helping patients adhere to their treatment regimens and manage the practical aspects of living with Hemophilia A. PSPs often provide drug compliance reminders and deliver valuable treatment information. However, patients feel that PSPs could offer more comprehensive

3. support for managing day-to-day challenges, staying active safely, and learning about new therapies. Patients have expressed a particular need for cost management support and digital tools, such as apps for monitoring bleeds and dosing. AI-Powered Insights into Technology in Hemophilia Care 1.Usage and Adoption of Apps TheAI-powered insightsfrom the study stated that digital tools like myPKFiT and WAPPS aim to simplify the coordination of Hemophilia A management. It provides functionality like infusion reminders, bleed logging and activity planning. However, these apps are still underutilized and often only used for specific activities, such as logging a bleed incident before a planned trip. Both apps face issues that hamper broader adoption, including limited usability, bugs, and challenging registration processes. 2.Desired App Features Patients are looking for apps that do more than basic disease management tasks; they seek features that integrate better into their daily routines, such as activity tracking, electronic health record (EHR) linkage, and direct communication with doctors. Enhancing these features could make the apps more central to patients’ lives and improve their engagement with technology-assisted care. Some additional AI-powered insights are hidden in the interest of confidentiality. AI-Powered Insights: Recommendations for Our Client 1.Highlighting A’s Legacy Given its long-standing presence in the market, A has a strong brand identity that our client can leverage. Reinforcing this legacy, engaging in Hemophilia-related activities, and involving loyal users in testimonials may help bolster A’s market position. Additionally, promoting the story of compliance with Factor VIII as a preventive measure against switching to alternative therapies could maintain A’s user base. 2.Supporting B’s Adoption For B to gain traction, our client may need to conduct regional campaigns to raise awareness and collaborate with medical associations to establish specific guidelines for its use. Additionally, providing economic data to justify B’s cost could increase its chances of inclusion in standard care guidelines across more countries. Gain AI-Powered Insights to Decide Smarter & Better Hemophilia A without inhibitors remains a complex condition with diverse treatment pathways and varying patient needs across countries. Moving forward, our client’s efforts to enhance awareness, provide support, and address the specific needs of patients and HCPs will be crucial in ensuring that people with Hemophilia A can access effective and sustainable care. Contact usat GrapheneAI to gain insights to help strategize your drug marketing for the betterment of people. Also, read about how our client was able to make asmarter decisionthrough our solution.